Slight body weight and systolic blood pressure reduction are important beneficial effects. Main adverse events of SGLT2 inhibitors are genital mycotic and urinary tract infections. Dapagliflozin ...

GLP-1 receptor agonists were more cardioprotective in younger people, but reduced HbA1c more with age. The age of type 2 ...

A new study finds SGLT2 inhibitors like Jardiance and GLP-1 drugs like Ozempic provide different benefits depending on the ...

SGLT2 inhibitors and GLP-1 agonists also reduced the risk of major adverse cardiovascular events ... despite the glucose lowering effects being less in older people,” he noted.

The study revealed a lower risk of nephrolithiasis with SGLT2 inhibitors than DPP4 inhibitors in both stone never-formers and ...

CardioOncology, shows that administration of the SGLT2 inhibitor empagliflozin to pigs receiving anthracyclines preserves ...

A team of scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC), working in collaboration with international partners, has designed a strategy for preventing the cardiotoxic ...

Starting SGLT2 inhibitors led to a lower risk of eGFR ... an elevated risk of type 2 diabetes and accelerated progression to adverse vascular complications including CKD compared to their European ...

The SGLT2 inhibitors, as a class ... Specifically, canagliflozin (Invokana; Janssen) and empagliflozin both reduced the risk of major adverse cardiovascular events compared with placebo in the CANVAS ...

SGLT2 inhibitors and GLP-1 agonists also reduced the risk of major adverse cardiovascular events ... despite the glucose lowering effects being less in older people,” he noted. SGLT2 inhibitors were ...